131 related articles for article (PubMed ID: 17766002)
21. A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report.
Pillot GA; Read WL; Hennenfent KL; Marsh S; Gao F; Viswanathan A; Cummings K; McLeod HL; Govindan R
J Thorac Oncol; 2006 Nov; 1(9):972-8. PubMed ID: 17409981
[TBL] [Abstract][Full Text] [Related]
22. A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancer.
Han JY; Shin ES; Lee YS; Ghang HY; Kim SY; Hwang JA; Kim JY; Lee JS
Pharmacogenomics J; 2013 Oct; 13(5):417-22. PubMed ID: 22664479
[TBL] [Abstract][Full Text] [Related]
23. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1.
Fan L; Zhang W; Guo D; Tan ZR; Xu P; Li Q; Liu YZ; Zhang L; He TY; Hu DL; Wang D; Zhou HH
Clin Pharmacol Ther; 2008 Mar; 83(3):471-6. PubMed ID: 17851565
[TBL] [Abstract][Full Text] [Related]
24. Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1.
Oswald S; König J; Lütjohann D; Giessmann T; Kroemer HK; Rimmbach C; Rosskopf D; Fromm MF; Siegmund W
Pharmacogenet Genomics; 2008 Jul; 18(7):559-68. PubMed ID: 18551036
[TBL] [Abstract][Full Text] [Related]
25. No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone.
Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M
Br J Clin Pharmacol; 2008 Jan; 65(1):78-86. PubMed ID: 17635496
[TBL] [Abstract][Full Text] [Related]
26. A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer.
Hotta K; Ueoka H; Kiura K; Tabata M; Kuyama S; Satoh K; Kozuki T; Hisamoto A; Hosokawa S; Fujiwara K; Tanimoto M
Lung Cancer; 2004 Jul; 45(1):77-84. PubMed ID: 15196737
[TBL] [Abstract][Full Text] [Related]
27. Irinogenetics: how many stars are there in the sky?
Mathijssen RH; Gurney H
J Clin Oncol; 2009 Jun; 27(16):2578-9. PubMed ID: 19349537
[No Abstract] [Full Text] [Related]
28. Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.
Sai K; Saito Y; Maekawa K; Kim SR; Kaniwa N; Nishimaki-Mogami T; Sawada J; Shirao K; Hamaguchi T; Yamamoto N; Kunitoh H; Ohe Y; Yamada Y; Tamura T; Yoshida T; Matsumura Y; Ohtsu A; Saijo N; Minami H
Cancer Chemother Pharmacol; 2010 May; 66(1):95-105. PubMed ID: 19771428
[TBL] [Abstract][Full Text] [Related]
29. Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients.
Sai K; Saito Y; Fukushima-Uesaka H; Kurose K; Kaniwa N; Kamatani N; Shirao K; Yamamoto N; Hamaguchi T; Kunitoh H; Ohe Y; Tamura T; Yamada Y; Minami H; Ohtsu A; Yoshida T; Saijo N; Sawada J
Cancer Chemother Pharmacol; 2008 Aug; 62(3):529-37. PubMed ID: 17992531
[TBL] [Abstract][Full Text] [Related]
30. Irinotecan pharmacogenetics: influence of pharmacodynamic genes.
Hoskins JM; Marcuello E; Altes A; Marsh S; Maxwell T; Van Booven DJ; Paré L; Culverhouse R; McLeod HL; Baiget M
Clin Cancer Res; 2008 Mar; 14(6):1788-96. PubMed ID: 18347181
[TBL] [Abstract][Full Text] [Related]
31. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
[TBL] [Abstract][Full Text] [Related]
32. Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy.
Han JY; Lee GK; Yoo SY; Yoon SJ; Cho EY; Kim HT; Lee JS
Pharmacogenomics J; 2010 Apr; 10(2):86-93. PubMed ID: 19859084
[TBL] [Abstract][Full Text] [Related]
33. OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers.
Wen J; Xiong Y
J Clin Pharm Ther; 2010 Feb; 35(1):99-104. PubMed ID: 20175818
[TBL] [Abstract][Full Text] [Related]
34. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism.
He YJ; Zhang W; Chen Y; Guo D; Tu JH; Xu LY; Tan ZR; Chen BL; Li Z; Zhou G; Yu BN; Kirchheiner J; Zhou HH
Clin Chim Acta; 2009 Jul; 405(1-2):49-52. PubMed ID: 19374892
[TBL] [Abstract][Full Text] [Related]
35. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.
Pasanen MK; Neuvonen M; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2006 Dec; 16(12):873-9. PubMed ID: 17108811
[TBL] [Abstract][Full Text] [Related]
36. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
Stewart CF; Panetta JC; O'Shaughnessy MA; Throm SL; Fraga CH; Owens T; Liu T; Billups C; Rodriguez-Galindo C; Gajjar A; Furman WL; McGregor LM
J Clin Oncol; 2007 Jun; 25(18):2594-600. PubMed ID: 17577039
[TBL] [Abstract][Full Text] [Related]
37. Establishment of an expression platform of OATP1B1 388GG and 521CC genetic polymorphism and the therapeutic effect of tamoxifen in MCF-7 cells.
Pu Z; Zhang X; Chen Q; Yuan X; Xie H
Oncol Rep; 2015 May; 33(5):2420-8. PubMed ID: 25812934
[TBL] [Abstract][Full Text] [Related]
38. OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation.
Zhang W; He YJ; Gan Z; Fan L; Li Q; Wang A; Liu ZQ; Deng S; Huang YF; Xu LY; Zhou HH
Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1240-4. PubMed ID: 17973861
[TBL] [Abstract][Full Text] [Related]
39. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.
de Jong FA; Scott-Horton TJ; Kroetz DL; McLeod HL; Friberg LE; Mathijssen RH; Verweij J; Marsh S; Sparreboom A
Clin Pharmacol Ther; 2007 Jan; 81(1):42-9. PubMed ID: 17185998
[TBL] [Abstract][Full Text] [Related]
40. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion.
Ohe Y; Sasaki Y; Shinkai T; Eguchi K; Tamura T; Kojima A; Kunikane H; Okamoto H; Karato A; Ohmatsu H
J Natl Cancer Inst; 1992 Jun; 84(12):972-4. PubMed ID: 1321253
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
